logo
Pediatrician Responds to Parents Who Called Measles 'Not That Bad' — After Their Unvaccinated Child Died (Exclusive)

Pediatrician Responds to Parents Who Called Measles 'Not That Bad' — After Their Unvaccinated Child Died (Exclusive)

Yahoo21-03-2025

The parents of an unvaccinated 6-year-old who died during the Texas measles outbreak called the highly contagious virus that infected all five of their children "not that bad"
In a controversial interview conducted by an anti-vaccine group, the parents said they "absolutely" would not get the shots — which pediatrician and infectious disease specialist Dr. Adam Ratner tells PEOPLE are the best way to prevent the infection
Dr. Ratner also responded to claims about how alternative remedies can help — and how the parents' statements that measles is good for the immune system are medically incorrect
The Texas parents of a child who died of measles in February have given their first, and only, filmed interview — a highly controversial one in which they refer to the disease that took their child's life as 'not that bad.'
In the March 17 interview with the anti-vaccine group Children's Health Defense (which was founded by Robert F. Kennedy Jr., Secretary of the U.S. Department of Health and Human Services) the parents, sometimes speaking Low German through a translator, defended their decision to not vaccinate their children against measles.
Instead, they explained that their six-year-old's death showed "it was her time," and "she was too good for this earth." The family also said they would "absolutely not take the MMR vaccine" — which protects against measles, mumps, and rubella — and shared that their four other children recovered quickly, crediting alternative solutions.
The child's death is the first U.S. fatality from the highly contagious illness in a decade, the Associated Press reports. According to the parents' interview, the child developed a fatal case of pneumonia, a common complication from the airborne virus.
To learn more about the controversial statements raised in the interview, PEOPLE spoke to pediatrician and infectious disease specialist Dr. Adam Ratner, author of Booster Shots: The Urgent Lessons of Measles and the Uncertain Future of Children's Health.
The parents said their other four children who had the measles 'got over it pretty quickly,' adding, 'the measles wasn't that bad.' Why do some people get sick from measles — and some die?
'In a lot of cases ,we don't know why one particular child will get sicker than another. There's not usually a good way of predicting that, and that's one of the reasons why it's so important for everyone to get vaccinated, because if you protect everybody, then you don't have to worry about that,' Dr. Ratner explained.
While 'the vast majority' of kids are sick for about a week, he says, 'some kids, including this six-year-old who died, can develop pneumonia or other adverse events, and they can end up needing to be hospitalized and can be sick for much longer — or, as she did, can go on to die.'
The parents said they would "absolutely not" get the MMR vaccine, and her father shared that measles 'are good for the body,' and can help protect people from getting cancer.
'None of that is true,' Dr. Ratner tells PEOPLE. 'Measles are not good for people in any way. They put children in grave danger as they did for that family's daughter. They put children at risk of other infections for a couple of years after measles. And there is no evidence that measles has any effect on risk for cancer or risk for anything else later on.'
As he explained, 'We now know that there are also some later onset issues that can come up with measles. There's a degenerative neurological condition called subacute sclerosing panencephalitis or SSPE,' which he explained can begin as early as seven years after a measles infection. 'That is a very serious disease that leads to death in almost all cases.'
She died from pneumonia — was that caused by measles or was it a secondary infection?
'You can get pneumonia from measles or kids with measles can develop a super infection, meaning bacterial pneumonia on top of measles,' Dr. Ratner tells PEOPLE, explaining that they could also get influenza or COVID. 'It's because they have the original viral infection. That sets them up to have a bacterial infection on top of it.'
'This is a very typical story,' he said. 'Kids with measles can seem like they're getting better and then can develop pneumonia later. Pneumonia can be from measles alone or measles plus a bacterial infection. But in either case, this whole course is preventable by vaccination."
Related: RFK Jr. Promotes Vitamin A, Vaccine 'Freedom of Choice' amid 'Rapidly' Expanding Measles Outbreak
The family talked about how the other children had breathing treatments and made a point that their daughter who died wasn't offered one. Why would breathing treatments be offered and would they be helpful?
'There's no evidence for either inhaled steroids, which is what budesonide is, or inhaled beta agonists like albuterol in measles,' Dr. Ratner explained. 'There's simply no evidence that they do anything.' As for the other children, whom the parents said benefitted from treatments, Dr. Ratner said 'it sounds like the other children had a more benign course so I think they were simply not as sick.'
What about other treatments that have been mentioned, like vitamin A and cod liver oil? Are they helpful in treating or preventing measles?
'The vitamin A thing is a little complicated because there's a kernel of truth in there,' he explained. 'Children who are malnourished are at higher risk of severe courses and death from measles, and we know from studies from decades ago that vitamin A supplementation for people who have measles can decrease — but not eliminate— the risk of death and severe disease.'
Dr. Ratner explained that if you're treating a patient with measles, 'it is reasonable to give two doses of vitamin A — just 2 doses, and under the supervision of a doctor — and that can help decrease the risk of severe disease and death from measles. It doesn't prevent either of those things, and it certainly does not prevent people from getting measles.'
There is also the risk of taking too much vitamin A, he explained. 'It accumulates in the body. It can cause liver damage. It can cause central nervous system damage. It can cause issues with skin — it is not a benign treatment."
And as for cod liver oil, while it 'does, in fact, contain some vitamin A' Dr. Ratner explained, there is 'no evidence that that helps in any way and giving a supplement that has an unknown amount of things in it is unlikely to be helpful.'
Related: 'Measles Parties' for Kids Are 'Terrifying' — and Could Have 'Devastating' Effects, Experts Say
The mother said she believes she had been vaccinated, and she still developed symptoms of measles. Why would that happen?
'Especially for someone who got a single dose of vaccine, there is some chance that, if they are exposed to measles, they can develop measles,' said Dr. Ratner, who explained that one dose of the MMR vaccine is 'about 93% effective,' and the two-dose regimen is 'about 97% effective.'
'Often those people have milder disease than people who haven't been vaccinated,' he said, 'and it sounds like her course was pretty mild.'
What do people need to realize about measles and their risk of infection?
'The only way to prevent measles is by vaccination. The vaccine is safe and it is highly effective, and we have been using it for 60 years at this point,' Dr. Ratner says. 'There is a lot of misinformation out there and what happens when you have that level of of misinformation, is that vaccine rates drop, you end up with large outbreaks like you have in West Texas now.'
'We've lost a child already in this outbreak and an adult has died in New Mexico. Both of those deaths were preventable,' he said. 'Measles is not supposed to be causing deaths in people in the U.S. in 2025, and so this is all preventable.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories
Read the original article on People

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'Euphoria' Star Addresses Their ALS Diagnosis for the First Time
'Euphoria' Star Addresses Their ALS Diagnosis for the First Time

Yahoo

time3 hours ago

  • Yahoo

'Euphoria' Star Addresses Their ALS Diagnosis for the First Time

A medical diagnosis is a deeply personal thing to Euphoria star Eric Dane. He shared the news with the world and that's enough. The 52-year-old actor revealed he had amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, to People in April. "I have been diagnosed with ALS,' Dane said to the publication. 'I am grateful to have my loving family by my side as we navigate this next chapter.' He is back on the set of the HBO show for Season 3 while also promoting his new Prime Video series, Countdown, premiering on June 25. Dane broke his silence with Variety in a June 12 interview that shows how focused he is on his Hollywood work — he prefers not to make the ALS announcement a hot topic. e "With real respect, I really don't want to talk about it," he told the media outlet. "I made the announcement. That's what's going on with me; it's very personal to me. And I just want to keep talking about Countdown.' Still, the gravity of the disease weighs on him because he wants to keep on working in the entertainment industry. "I am ready and willing to do just about anything, but I have limitations that I understand will preclude me from playing certain roles," Dane said confidently. "I'm working on Euphoria. I finished Countdown. As far as that goes, I'm pretty capable." According to the Mayo Clinic, ALS is a "nervous system disease that affects nerve cells in the brain and spinal cord" which causes the loss of muscle control. There is currently no cure for the fatal disease, and the symptoms get worse over time.'Euphoria' Star Addresses Their ALS Diagnosis for the First Time first appeared on Men's Journal on Jun 12, 2025

Do you need tattoo anesthesia or a measles vaccine? What to know
Do you need tattoo anesthesia or a measles vaccine? What to know

Miami Herald

time3 hours ago

  • Miami Herald

Do you need tattoo anesthesia or a measles vaccine? What to know

Health Care Do you need tattoo anesthesia or a measles vaccine? What to know This collection of stories explores health-related decisions, including vaccination and and anesthesia. Measles cases rise across the U.S., prompting questions about the need for additional MMR vaccinations. Vaccinated individuals usually have lifelong immunity, but checking immunization records proves essential. In Miami, some opt for sedation tattooing to alleviate pain and hasten completion. Sedation Ink combines tattoo artistry and medical oversight to ensure client safety and efficiency. Read the stories below. Sedation Ink artists work on a back tattoo for client Dom Groenveld as he is anesthetized at a surgical office on Monday, Jan. 20, 2025, in Miami, Fla. Sedation Ink offers tattooing under anesthesia, allowing clients to complete extensive body art in a single session. By Photo by Matias J. Ocner NO. 1: DO YOU NEED ANESTHESIA TO GET A TATTOO? SEE HOW A MIAMI STUDIO MIXES MEDICINE AND INK What to know about the studio sedation. | Published February 26, 2025 | Read Full Story by Michelle Marchante A 3D graphical representation of a measles virus particle. NO. 2: DID YOU GET THE MEASLES VACCINE IN THE PAST? DO YOU NEED ANOTHER SHOT? HOW TO CHECK What to know about how long it lasts. | Published March 15, 2025 | Read Full Story by Michelle Marchante The summary above was drafted with the help of AI tools and edited by journalists in our News division. All stories listed were reported, written and edited by McClatchy journalists.

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Yahoo

time3 hours ago

  • Yahoo

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff Enliven will host a webcast and conference call today, June 13, at 1:30 p.m. ET BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) in an oral presentation at the European Hematology Association (EHA) 2025 Congress taking place June 12-15 in Milan, Italy, and virtually. "Thanks to the success of tyrosine kinase inhibitors (TKIs), patients with CML now have a near-normal life expectancy. As a result, treatment goals have evolved beyond response and survival to also prioritize quality of life and tolerability," said Andreas Hochhaus, Professor of Internal Medicine, Hematology and Oncology and Head of the Department of Hematology and Medical Oncology at the Jena University Hospital, Germany. "However, significant unmet needs remain, particularly related to treatment resistance and intolerance, across all lines of therapy. The data from ELVN-001 are encouraging, showing an efficacy, safety and tolerability profile that compare favorably to approved BCR::ABL1 inhibitors, despite being studied in a more heavily pretreated population. I look forward to future data, which could support ELVN-001 as a promising new option for patients who need better long-term disease management." "We are highly encouraged by the ELVN-001 data, specifically as it relates to the consistency of the cumulative and achieved MMR rates as the Phase 1 trial progresses, with more evaluable patients and longer duration of treatment," said Helen Collins, M.D., Chief Medical Officer of Enliven. "While MMR is the efficacy endpoint in CML, safety and tolerability are equally critical given the chronic nature of the disease. ELVN-001 was reported to be well tolerated across all evaluated doses and had low levels of dose reductions and discontinuations, which we believe is the key sign of a favorable safety and tolerability profile. We believe ELVN-001 has the potential to offer best-in-class efficacy and tolerability, which are key attributes for people living with CML. We look forward to sharing additional data in the future." ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with CML. ELVN-001 Data Highlights Patient Demographics As of the cutoff date of April 28, 2025, 90 patients have been enrolled in the ongoing Phase 1 trial across dose levels ranging from 10 mg once a day (QD) to 80 mg twice a day (BID). The vast majority of patients (80%) remain on study with a median treatment duration of ~29 weeks. Patients enrolled were heavily pretreated: 67% of patients received three or more unique prior TKIs, including 58% of patients who received prior asciminib and 43% of patients who received prior ponatinib. 72% of patients had discontinued their prior TKI due to lack of efficacy. Encouraging ELVN-001 Efficacy Data by 24 Weeks Of the enrolled patients, 53 with typical BCR::ABL1 transcripts and without T315I mutations were evaluable for major molecular response (MMR) by 24 weeks. 25 of 53 (47%) evaluable patients were in MMR by 24 weeks, with 13 of 41 (32%) achieving and 12 of 12 (100%) maintaining MMR. Of those resistant to their last TKI, 14 of 34 (41%) were in MMR by 24 weeks. Of those previously treated with asciminib or ponatinib, 12 of 34 (35%) were in MMR by 24 weeks. All patients who achieved or maintained MMR were still in MMR at the time of data cutoff. These data continued to compare favorably to precedent Phase 1 MMRs for approved BCR::ABL1 TKIs, particularly given the more heavily pretreated patient population in the ELVN-001 clinical trial. Specifically, the achieved MMR rate by 24 weeks of 32% compares favorably with historical data from less heavily pretreated patients receiving asciminib, which showed achieved MMR rates of 24% in the Phase 1 trial and 25% in the ASCEMBL Phase 3 trial. ELVN-001's Safety Profile Consistent with High Selectivity for ABL1 ELVN-001 remains well-tolerated across all evaluated doses. Only 3.4% (3 of 87) of patients had dose reductions due to treatment-emergent adverse events (TEAEs) and 4.6% (4 of 87) of patients discontinued due to TEAEs. The majority of TEAEs were low frequency and low grade, and the hematologic TEAE profile was similar to or better than the approved TKIs. Only 2.3% (2 of 87) of patients experienced ≥ Grade 3 non-hematologic treatment-related AEs. No evidence to date of enhanced cardiovascular toxicity and no treatment-related arterial occlusive events (AOEs). The maximum tolerated dose was not reached, and no exposure-toxicity relationship was observed. ELVN-001 Pharmacokinetic (PK) Profile The PK profile supports once-daily dosing with flexible administration requirements, including the ability to take with or without food. There is low potential for drug-drug interactions, an important advantage given that the average CML patient takes approximately five concurrent medications. "We believe there remains significant opportunity to improve upon existing therapies," said Sam Kintz, Co-founder and Chief Executive Officer of Enliven. "Based on today's encouraging Phase 1 update, we believe ELVN-001 has the potential to compete across all lines of therapy. We believe that precedent registrational trials in CML provide a roadmap for the regulatory pathway for ELVN-001, and the use of biomarker-based endpoints, like MMR, enables smaller, faster studies. Importantly, historical Phase 1 data in late-line CML trials have predicted success in subsequent pivotal trials. Building off this exciting update, we expect to initiate our first head-to-head Phase 3 pivotal trial in 2026 and remain confident in ELVN-001 and its potential positioning in the future in the CML treatment paradigm." The oral presentation titled: "ENABLE: A Phase 1a/1b Study of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated CML" will be presented by Andreas Hochhaus, Professor of Internal Medicine, Hematology and Oncology and Head of the Department of Hematology and Medical Oncology at the Jena University Hospital, Germany later today. A copy of the presentation will be available on the "Program Presentations & Publications" section of the Company's website at Webcast and Conference Call InformationEnliven will host a live webcast and conference call today at 1:30 p.m. ET / 7:30 p.m. CEST. To participate in the live event, please register using this link. Following registration, participants will have access to dial in numbers and a unique passcode should they prefer to participate by phone. The event and accompanying slides can also be accessed by visiting the investor relations section of the Company's website at An archived webcast will be available on the Company's website following the event. About the ENABLE TrialThe ENABLE study (NCT05304377) is a Phase 1 study of ELVN-001 in patients with previously treated CML. The trial is currently in Phase 1a/1b development and is a dose escalation and expansion trial designed to evaluate safety and tolerability and to determine the recommended dose for further clinical evaluation of ELVN-001 in patients with CML with and without T315I mutations that is relapsed, refractory or intolerant to TKIs. Secondary endpoints include pharmacokinetics, MMR by central quantitative reverse transcriptase polymerase chain reaction, duration of MMR, BCR::ABL1 transcript levels and complete hematologic response. Enliven is preparing for the potential start of a pivotal trial for ELVN-001 in 2026. About ELVN-001ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. As a highly selective active site inhibitor, ELVN-001 has a mechanism of action that is complementary to allosteric BCR::ABL1 inhibitors, which may play an increasingly important role in the standard of care. ELVN-001 was also designed to have activity against the T315I mutation, the most common BCR::ABL1 mutation, which confers resistance to nearly all approved TKIs, as well as activity against mutations known to confer resistance to allosteric BCR::ABL1 inhibitors. About Enliven Therapeutics Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. Forward-Looking StatementsThis press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations and financial condition, or otherwise, based on current beliefs of the management of Enliven, as well as assumptions made by, and information currently available to, management of Enliven. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of, and plans regarding, market opportunities, and expectations regarding Enliven's programs, including ELVN-001; expected milestones for ELVN-001, including the potential timing for a start of a pivotal trial for ELVN-001; and statements by Enliven's Chief Executive Officer, Chief Medical Officer and the Professor of Internal Medicine, Hematology and Oncology and Head of the Department of Hematology and Medical Oncology at the Jena University Hospital, Germany. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation: the limited operating history of Enliven; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize or license, or identify and complete strategic alternatives for, product candidates; the outcome of preclinical testing and early clinical trials for product candidates and the potential that the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, including extrapolations or predictions regarding the safety and efficacy of ELVN-001 based on comparisons to published results of trials of other products, which may be different when evaluated in head-to-head studies; Enliven's limited resources; the risk of failing to demonstrate safety and efficacy of product candidates; Enliven's limited experience as a company in designing and conducting clinical trials; the potential for interim, topline, and preliminary data from Enliven's preclinical studies and clinical trials to materially change from the final data; potential delays or difficulties in the enrollment or maintenance of patients in clinical trials; developments relating to Enliven's competitors and its industry, including competing product candidates and therapies; the potential market opportunity for any of Enliven's programs; the decision to develop or seek strategic collaborations to develop Enliven's current or future product candidates in combination with other therapies and the cost of combination therapies; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven's patent protection; reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners; geo-political developments, general market or macroeconomic conditions; Enliven's ability to obtain additional capital to fund Enliven's general corporate activities and to fund Enliven's research and development; and other risks and uncertainties, including those more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), which may be found in the section titled "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and 10-Q filed with the SEC and in Enliven's future reports to be filed with the SEC. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Head-to-Head Comparisons The Company has not performed any head-to-head trials for ELVN-001. As a result, the data referenced in this press release is derived from different clinical trials at different points in time, with differences in trial design and patient populations. As a result, conclusions from cross-trial comparisons cannot be made. View original content to download multimedia: SOURCE Enliven Therapeutics, Inc. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store